Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2006

01-11-2006 | Phase II Studies

Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study

Authors: James H. Doroshow, Sheryl McCoy, John S. Macdonald, Brian F. Issell, Taral Patel, Patrick W. Cobb, Kathleen J. Yost, James L. Abbruzzese

Published in: Investigational New Drugs | Issue 6/2006

Login to get access
Metadata
Title
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study
Authors
James H. Doroshow
Sheryl McCoy
John S. Macdonald
Brian F. Issell
Taral Patel
Patrick W. Cobb
Kathleen J. Yost
James L. Abbruzzese
Publication date
01-11-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 6/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-9244-8

Other articles of this Issue 6/2006

Investigational New Drugs 6/2006 Go to the issue

Preclinical Studies

MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53

Phase II studies

Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

Phase I Studies

Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS)

Preclinical Studies

Studies on reaction of amino acids and triplet thioxanthone derivatives by laser flash photolysis

Phase II Studies

A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145

Preclinical Studies

Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits